Background: Whilst it is well known that opioids depress the immune system, the site(s) of action for this depression is highly controversial. Immune modulation could occur directly at the immune cell or centrally via the hypothalamic-pituitary-adrenal axis. In a number of studies using individual enriched immune cell populations we have failed to detect classical MOP (µ), DOP (δ) and KOP (κ) receptors. The non-classical nociceptin/orphanin FQ (N/OFQ) receptor, NOP is expressed on all cells so far examined. Our hypothesis was that immune cells do not express classical opioid receptors and that using whole blood would definitively answer this question.
Introduction
Opioid receptors are classified as both classical -MOP (µ), DOP (δ) and KOP (κ) -and nonclassical NOP (nociceptin/orphanin FQ peptide) receptors. A causal link between opioids and immune function has been historically presumed, based on observations of opioid addicts having an increased incidence and severity of infections. 1 2 More recent evidence highlights how opioids can have an effect on endocrine and immune function. 3 However, the immunomodulatory effects of opioids have not been determined precisely, with various opioid drugs having different effects on immune function, despite targeting a single receptor subtype, the MOP receptor. [4] [5] [6] Moreover, elucidating the mechanism(s) by which opioids modulate immune function is confounded by interspecies differences in their immunomodulatory effects. Hence opioid immunological interactions are both drug and species dependent. In MOP receptor knockout animal studies, no opioid immune modulation is seen, providing robust evidence that this receptor is the biological target. 7 8 One of proposed mechanisms for the immune modulatory action of opioids is a direct action on immunocytes; however there is huge controversy as to whether or not classical opioid receptors are expressed on these cells. Whilst there is still a strong belief that peripherallymediated immune modulatory effects of opioids are facilitated through receptors expressed on immunocytes, and several studies have determined the presence of opioid receptors on peripheral blood mononuclear cells (PBMCs), our group has been unable to detect classical opioid receptor expression on immunocytes in several settings and using a series of detection methodologies: fluorescent/immunofluorescent labelling, quantitative PCR and Western blotting. [9] [10] [11] [12] [13] Previous studies have focused on individual populations of immune cell types, in one study NOP receptor mRNA and mRNA for the precursor protein of N/OFQ (ppNOC) was differentially detected in granulocytes, monocytes and lymphocytes; MOP receptor mRNA was not detected in any cell type. [11] [12] [13] [14] [15] We therefore aimed to take a more systematic approach using several PCR methodologies to investigate opioid receptor expression in unstimulated blood from healthy volunteers. It is possible that opioid treatment or the presence of sepsis might upregulate expression so we additionally treated whole blood with supraclinical concentrations of morphine and fentanyl and lipopolysaccharide (LPS) and peptidoglycan G (PepG), agents commonly used to mimic sepsis.
Our hypothesis was that immune cells do not express classical opioid receptors and that using whole blood would definitively answer this question.
General Methodology

Blood collection
Venous blood was collected from 10 healthy volunteers from the University Deptartment of Cardiovascular Sciences, Division of Anaesthesia, Critical Care and Pain Management, with approval from the University of Leicester (volunteer) research ethics committee and with informed consent. Up to 30mls of venous blood was collected using EDTA-monovette® tubes and divided into sterile 2ml tubes to which Lipopolysaccharide from Escherichia coli 0111:B4 (Sigma, UK) (LPS) 5µg/ml, Staphylococcus Aureus Peptidoglycan (Sigma, UK) (PEPG), 20µg ml -1 , fentanyl 10µM (Tocris, UK), morphine 10µM (Sigma, UK), were added separately and in combinations as indicated in results. Samples were incubated for 24hrs at 37.0°C in 5% CO 2 humidified air.
Tissue culture
Positive control samples were prepared using Chinese Hamster ovary cells (CHO) expressing human KOP, DOP, NOP receptors and Human Embryonic Kidney (HEK) cells expressing human MOP. CHO hKOP/DOP cells were cultured in Hams F12, CHO hNOP in DMEM/Hams F12 (1:1) and HEK hMOP cells in MEM, all media were supplemented with 10% FCS, Penicillin (100IU/ml), Fungizone (2.5µg/ml), and streptomycin (100µg ml -1 ). For maintaining expression of inserted genes, stock cultures of cells were additionally supplemented with 200µg ml -1 of G418for classical opioid receptors MOP/KOP/DOP, and 200µg ml -1 of G418 and Hygromycin B for CHO hNOP . Raji cells (lymphoblast-like cell) were used as an additional cell expressing DOP and cultured in RMPI 1640 supplemented with 10% FCS, Penicillin (100IU/ml), Fungizone (2.5µg ml -1 ), streptomycin (100µg ml -1 ) and Glutamine (2mM). All cells were cultured at 37.0°C and 5% CO 2 humidified air. All tissue culture media were from Sigma (UK) and supplements were from Invitrogen Invitrogen -Thermo Fisher Scientific (UK).
RNA Extraction, cDNA synthesis and QPCR
Total RNA was purified from whole blood samples using a RiboPure™ RNA Purification Kit 
Methods and Results
Volunteer characteristics were 4 females and 6 males, mean age 40.6 years (range 32-54 years), mean weight 86.4kg (range 55-110kg) and mean height 174.9 cm (range 153-196 cm).
MOP/KOP
Whole blood was collected and incubated overnight with the inflammatory mediators LPS
and PepG in the absence and presence of clinical MOP receptor agonists morphine and fentanyl (supraclinical concentrations) as noted above. Additional untreated (plain) and media (vehicle) treated controls were included. cDNA from whole blood samples and cell lines were probed for gene transcripts using; quantitative PCR (qPCR) with commercially available TaqMan probes (Thermo Fisher Scientific, UK), SYBR Green and predesigned, target-validated primer pairs (Qiagen and Sigma, UK) ( Table 1) . Relative gene expression quantification was determined using TaqMan endogenous control probes, human beta-2microglobulin (B2M) and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and assays run in a duplex format. QPCR reactions were run on a StepOne instrument (applied Biosystems, UK), the thermal profile for reactions with TM-MOP1, TM-KOP1, TM-NOP1, TM-DOP1&2 and endogenous control probes was 2min at 50˚C, 10min at 95˚C followed by 40 cycles of 15s at 95˚C and 1min at 60˚C, for TM-DOP3 probes 3min at 95˚C followed by 40 cycles of 3s at 95˚C and 30s at 60˚C.
In qPCR experiments with mRNA extracted from whole blood samples, probing for KOP and MOP expression, no amplification of these receptor transcripts could be detected. In the same samples there was robust amplification of endogenous controls B2M and GAPDH which was consistent across the various blood treatments with Ct values not varying significantly from one another (Kruskal-Wallis and Dunn's multiple comparison p>0.05) ( Table 2) . Positive control cDNA from CHO hKOP and CHO hMOP cells verified the probes with Ct values of 22.55 and 24.07 respectively. This absence of KOP and MOP receptor expression is similar to our previous studies in more discrete populations of white blood cells; PBMCs and polymorphonuclear cells. 10 12 14 15 NOP Relative gene expression quantification for NOP receptor transcripts was determined using two TaqMan endogenous control probes, human B2M and human GAPDH in a duplex assay format with NOP TaqMan probes. NOP expression was detected in untreated whole blood samples, median ∆C t of 10.40 (range 8.56-11.24), and in all treated samples ( Table 2 ).
The effect of LPS, PepG or a combination of the two on NOP mRNA were determined by normalized target gene expression level using the equation 2( -ΔΔCt ), where ΔΔCt = ΔCt (treated) -ΔCt (control; media). The calculated fold-change (2( -ΔΔCt )) of NOP mRNA levels decreased significantly relative to vehicle treated control samples after treatment with LPS, PepG or the two combined ( Figure 2 ).
DOP
In qPCR experiments with TaqMan probes designed and validated for the human DOP receptor, TM-DOP1-3, amplification in both positive control cDNA from CHO cells transfected with the human DOP receptor and in cDNA from whole blood samples was detected. Moreover, amplification of DOP receptor transcripts was also detected in nontemplate controls (NTCs) from whole blood samples for all those TaqMan probes (Table 1) .
NTC represent a negative control run in parallel for each sample for which the reverse transcriptase enzyme, which converts mRNA to cDNA, is removed and therefore amplification in these samples represents genomic DNA contamination and not mRNA In an effort to distinguish cDNA from gDNA primers were designed which span an exon/exon boundary using primer-BLAST against the NCBI Reference Sequence NM_000911.3 for the Homo sapiens opioid receptor, delta 1 (OPRD1) mRNA. These primers designated STD-DOP-1 were used in end-point PCR using AmpliTaq Gold® 360
Master Mix (Thermo Fisher Scientific, UK) on an Eppendorf Mastercycler with an initial 95°C 10 min denaturing step followed by 40 cycles of 30s at 95°C, annealing for 30s between at temperatures 51˚C -71.5˚C and extension at 72˚C for 60s with a final extension for 10min at 72˚C. PCR products were run on a 3% agarose gel stained with ethidium bromide and imaged under UV illumination.
STD-DOP-1 primers where initially used at a concentration of 0.4µM and with an annealing temperature of 59˚C and were determined to amplify a product of predicted size ~700bp in cDNA from CHO hNOP . In NTC wells from whole blood samples the STD-DOP 1 primer pair was seen to amplify a product of ~700bp and another ~200bp, although this was not consistent for all NTC samples tested. In order to improve the stringency of the STD-DOP 1 primer pair, temperature and concentration gradients were performed leading to the determination of an optimum annealing temperature at 56.5˚C and primer pair concentration of 40nM. Under these conditions, in cDNA from CHO hDOP cells, amplification was of a product of predicted size, ~700bp, and no product could be detected in NTCs. STD-DOP 1 primers were subsequently used under the same experimental conditions to probe samples for expression of the DOP in whole blood samples and no expression could be detected ( Figure   1 ).
Discussion
Our main finding using qPCR is that mRNA encoding for either the MOP or KOP receptor could not be detected in peripheral whole human blood under resting conditions or after incubation with a variety of inflammatory mediators and opioids. A false positive DOP receptor mRNA signal was initially detected, since a variety of the commercially available TaqMan probes for this receptor transcript did not differentiate genomic from copy DNA.
The presence of DOP receptor transcript was subsequently disproved through the development of a primer pair utilised in end-point PCR experiments. These data further underscore the need for carefully controlled PCR protocols. Transcripts encoding for the NOP receptor were consistently detected in whole blood samples and these decreased in the presence inflammatory stimuli (LPS and PepG).
In this study, the full complement of cell populations in whole blood, comprising red blood cells, white blood cells and platelets, were utilised with a range of experimental conditions, to include the effects of inflammatory stimuli (alone and in combination) and a number of clinically used MOP receptor agonists. This approach was used in conjunction with a comprehensive series of opioid receptor primers to fully establish expression, and to allow for measuring changes in expression of both classical and non-classical opioid receptor subtypes, in the mRNA from whole blood. Expression of classical opioid receptors on immune cells is hugely controversial and has profound consequences for studies into and clinical modulation of immune function by opioid drugs. 3 The physiological and cellular mechanisms that result in the immunosuppressant effect of opioid drugs seen in humans and whole animal studies is hypothesised to be mediated either through a direct action on immunocytes, altering sympathetic activity or modulation of the hypothalamic-pituitary-axis. 17 In addition, there is evidence for further central effects at glia.
Findings from our laboratory have shown that peripheral blood mononuclear leukocytes (PBMCs) do not express classical opiate receptors and therefore the functional action of opioid drugs on immune functioning is unlikely to be through opioid receptors expressed on these cells. 10 14-16 This finding is disputed by some studies which have identified the presence of MOP receptors on PBMCs. 5, 11, 15, 17, 18 In order to explore the hypothesis that opioid drugs can have a direct action on immunocytes, the expression of opioid receptor subtypes was determined using total RNA extracted from whole blood. It was believed that this approach could allow for detection of opioid receptor transcripts that may have been missed in discrete cells up-regulates the MOP receptor, which may suggest that the type, concentration and exposure time of the pro-inflammatory mediators used in this study were not optimal. 14 19 It is worthy of mention that the Kraus study did use multiple rounds of PCR to detect MOP receptor transcripts which suggest an extremely low quantity of transcript. 14 cDNA from whole blood RNA was initially probed for presence of human DOP receptor Recent studies have indicated that the nociceptin system has a role in inflammation and sepsis. 20 21 Clinical evidence from ICU patients diagnosed with sepsis has shown how there is a decrease in mRNA encoding for the NOP receptor in septic patients when compared with a matched control volunteer. Previously we have demonstrated that while PBMCs lack expression of classical opioid receptors (MOP, DOP, KOP), they do express NOP receptor transcripts and further studies have revealed differential expression on different white cell types, ∆C t of 6.43 in monocytes, ∆C t 8.05 in lymphocytes and ∆C t of 7.73 in granulocytes. 15 In mRNA extracted from whole untreated blood, expression of the NOP was further detected with a ∆C t 10.40. In the presence of LPS and PepG the calculated fold-change (2( -ΔΔCt )) for NOP mRNA levels decreased ( Figure 2) . These findings are similar to the decrease in NOP mRNA measured in ICU patients diagnosed with sepsis. 20
Limitations.
One obvious limitation of this study is the fact that we did not show the presence or absence of opioid receptor protein. There are two points of note in this regards. First without the presence of a transcribed gene; i.e., no receptor mRNA there can be no translated protein.
Secondly and despite considerable efforts in looking (see 22 ) there are no antibodies with proven selectivity for a particular member of the opioid receptor family.
In summary, using whole blood from healthy volunteers that should contain the full range of circulating immune cells, we failed to detect transcripts for MOP, DOP or KOP receptors, but NOP mRNA was present. We therefore conclude that immune modulation produced by MOP agonists in clinical practice (morphine and fentanyl) cannot occur at the level of the circulating immune cell as there is no target for interaction. 
